Thalidomide-O-C5-acid

Background Introduction

Thalidomide-O-C5-acid is a specialized E3 ligase ligand-linker conjugate designed for advanced applications in targeted protein degradation technologies, particularly PROTAC (Proteolysis Targeting Chimera) development. By leveraging the molecular framework of thalidomide, this compound serves as an essential building block to recruit the CRBN (Cereblon) E3 ubiquitin ligase within various bioconjugation and drug discovery platforms.

Mechanism

Thalidomide-O-C5-acid operates by binding to the Cereblon (CRBN) E3 ubiquitin ligase complex via its thalidomide moiety. The C5-alkyl acid linker introduces a functional handle for conjugation with diverse target protein ligands. When assembled as part of a PROTAC molecule, Thalidomide-O-C5-acid physically bridges the E3 ligase and the target protein, facilitating proximity-induced ubiquitination. This tagging marks the target for proteasomal degradation, enabling selective and efficient depletion of disease-related proteins from cells.

Applications

Thalidomide-O-C5-acid is widely utilized in the design, synthesis, and optimization of PROTACs, allowing researchers to target previously 'undruggable' proteins for degradation. Its modular structure supports the rapid generation of bifunctional molecules tailored for cancer, neurodegenerative, and autoimmune disease research. Furthermore, it serves as a versatile research tool in chemical biology, drug target validation, and next-generation therapeutics development—making it crucial for laboratories and pharmaceutical companies focused on protein-level drug discovery.

• Carboxylic acid-functionalized linker enables versatile conjugation to diverse warheads, facilitating custom PROTAC design.
• Optimized for efficient CRBN E3 ligase recruitment, supporting reliable and reproducible PROTAC synthesis.

The Thalidomide-O-C5-acid is an E3 Ligase Ligand-Linker Conjugate integral to PROTACs, facilitating targeted protein degradation by bridging the target protein and the E3 ligase. This conjugate enhances selective protein degradation, offering researchers a robust tool for studying protein function and potential therapeutic applications. The following provides a detailed description of this molecule.

Linker: The linker in Thalidomide-O-C5-acid is a five-carbon chain, offering moderate flexibility that allows for optimal spatial orientation between the ligand and target protein. Its non-cleavable nature ensures stability and durability during the degradation process, enhancing the efficacy of the PROTAC.

Ligand: The ligand component is derived from thalidomide, a well-characterized E3 ligase recruiter. Its phthalimide moiety is crucial for binding to cereblon, an E3 ubiquitin ligase, thereby promoting ubiquitination and subsequent degradation of the target protein.

Reactive Site: The reactive site of this molecule is an acid functional group, poised for coupling with amine-containing target protein ligands. Recommended reaction types include amide bond formation, which is both efficient and reliable for creating stable conjugates in a laboratory setting.

Recommended Target Protein Ligand: A suitable warhead for this conjugate is an amine-containing molecule, which can efficiently form a stable amide linkage with the acid group. This compatibility allows for the precise targeting of proteins with accessible lysine residues, making it advantageous for the study of protein interactions and the development of novel therapeutic strategies.